Randomized Trial of Treatments for Convergence Insufficiency

NCT ID: NCT00347945

Last Updated: 2006-07-04

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 90 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2000-10-31
• Study Completion Date: 2001-11-30

Brief Summary

The Convergence Insufficiency Treatment Trial (CITT) is a multi-center, placebo-controlled, single-masked, clinical trial designed to compare the benefits of two commonly used treatment approaches for patients with convergence insufficiency (CI)

Detailed Description

Considerable controversy exists regarding the best treatment for convergence insufficiency (CI), a common condition that often interferes with the ability to perform near work. The two most widely used treatments have significant differences in costs and in practitioner perceived utility. Pencil push-up therapy (PPT) is a simple, low-cost treatment in which patients are prescribed a single procedure to perform at home with only periodic follow-up. Office-based vision therapy (OBVT) is a more comprehensive, time-consuming, complex, and costly treatment in which patients are scheduled for weekly in-office therapy visits and are often prescribed a specific sequence of therapeutic procedures to perform at home. It is important to consider whether either, neither, or both treatments are effective.

The Convergence Insufficiency Treatment Trial (CITT) is a prospective, masked-examiner, multi-center clinical trial in which patients are randomized to one of these two treatment approaches. The primary goal is to answer the following question:

After 12 weeks of treatment, is one therapy more effective than the other in improving CI signs and symptoms? We will test the null hypothesis that there is no difference in the distribution of outcomes between the two populations.

The primary outcome measure will be a classification of each patient as a "success," "improvement," or "failure." This classification will be based on the level of improvement in both the signs (near point of convergence and positive fusional vergence) and symptoms of CI.

Additional questions relate to longer term effects:

1. Are the patients who were classified as "success" or "improvement" at twelve weeks the same at the one-year follow-up for each treatment group?

2. Are there differences in the distributions of changes in near point of convergence, positive fusional vergence, or accommodative amplitudes, between the two treatment groups, at twelve weeks and at one-year of follow up?

Conditions

Convergence Insufficiency

Keywords

convergence insufficiency, vision therapy, orthoptics

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Interventions

Pencil Push-ups

Intervention Type: PROCEDURE

Office-based Vision Therapy

Intervention Type: PROCEDURE

Placebo Office-based Vision Therapy

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

• Age 9-30 years
• Best corrected visual acuity of 20/25 in both eyes at distance and near
• Willingness to wear eyeglasses or contact lenses to correct refractive error, if necessary
• Exophoria at near at least 4 prism diopters greater than at far
• Insufficient positive fusional convergence (i.e., failing Sheard's criterion or minimum normative positive fusional vergence (PFV) of 15 base-out break).
• Receded near point of convergence of > 6 cm break.
• Normal random dot stereopsis using a 500 seconds of arc target.
• CI Symptom Survey score > 16 for subjects in 9-18 year age range and > 21 for subjects in the 19-30 year age range.
• Informed consent and willingness to participate in the study and be randomized

Exclusion Criteria

• CI previously treated with pencil push-ups (no more than 2 months of treatment within the past year)
• CI previously treated with office-based vision therapy/orthoptics (no more than 2 months of treatment within the past year)
• Amblyopia
• Constant strabismus
• History of strabismus surgery
• Anisometropia >1.50D difference between eyes
• Prior refractive surgery
• Vertical heterophoria greater than 1 
• Systemic diseases known to affect accommodation, vergence, and ocular motility such as: multiple sclerosis, Graves's thyroid disease, myasthenia gravis, diabetes, and Parkinson disease
• Any ocular or systemic medication known to affect accommodation or vergence
• Monocular accommodative amplitude less than 4 D in either eye as measured by the Donder's push-up method
• Manifest or latent nystagmus
• Attention deficit hyperactivity disorder (ADHD) or learning disability diagnosis by parental report
• Household member or sibling already enrolled in the CITT
• Any eye care professional, technician, medical student, or optometry student

• Minimum Eligible Age: 9 Years
• Maximum Eligible Age: 30 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

National Eye Institute (NEI)

NIH

Sponsor Role: collaborator

Pennsylvania College of Optometry

INDUSTRY

Sponsor Role: lead

Principal Investigators

Mitchell Scheiman, OD

Role: STUDY_CHAIR

Pennsylvania College of Optometry

Locations

Southern California College of Optometry

Fullerton, California, United States

State University of New York, College of Optometry

New York, New York, United States

The Ohio State University, Optometry Coordinating Center

Columbus, Ohio, United States

The Ohio State University

Columbus, Ohio, United States

Pacific University College of Optometry

Forest Grove, Oregon, United States

Eye Institute, Pennsylvania College of Optometry

Philadelphia, Pennsylvania, United States

University of Houston, College of Optometry

Houston, Texas, United States

Countries

United States

References

Borsting EJ, Rouse MW, Mitchell GL, Scheiman M, Cotter SA, Cooper J, Kulp MT, London R; Convergence Insufficiency Treatment Trial Group. Validity and reliability of the revised convergence insufficiency symptom survey in children aged 9 to 18 years. Optom Vis Sci. 2003 Dec;80(12):832-8. doi: 10.1097/00006324-200312000-00014.

Reference Type: BACKGROUND

PMID: 14688547 (View on PubMed)

Gallaway M, Scheiman M, Malhotra K. The effectiveness of pencil pushups treatment for convergence insufficiency: a pilot study. Optom Vis Sci. 2002 Apr;79(4):265-7. doi: 10.1097/00006324-200204000-00013.

Reference Type: BACKGROUND

PMID: 11999152 (View on PubMed)

Scheiman M, Cooper J, Mitchell GL, de LP, Cotter S, Borsting E, London R, Rouse M. A survey of treatment modalities for convergence insufficiency. Optom Vis Sci. 2002 Mar;79(3):151-7. doi: 10.1097/00006324-200203000-00009.

Reference Type: BACKGROUND

PMID: 11913841 (View on PubMed)

Scheiman M, Mitchell GL, Cotter S, Cooper J, Kulp M, Rouse M, Borsting E, London R, Wensveen J; Convergence Insufficiency Treatment Trial Study Group. A randomized clinical trial of treatments for convergence insufficiency in children. Arch Ophthalmol. 2005 Jan;123(1):14-24. doi: 10.1001/archopht.123.1.14.

Reference Type: RESULT

PMID: 15642806 (View on PubMed)

Scheiman M, Mitchell GL, Cotter S, Kulp MT, Cooper J, Rouse M, Borsting E, London R, Wensveen J. A randomized clinical trial of vision therapy/orthoptics versus pencil pushups for the treatment of convergence insufficiency in young adults. Optom Vis Sci. 2005 Jul;82(7):583-95. doi: 10.1097/01.opx.0000171331.36871.2f.

Reference Type: RESULT

PMID: 16044063 (View on PubMed)

Scheiman M, Kulp MT, Cotter SA, Lawrenson JG, Wang L, Li T. Interventions for convergence insufficiency: a network meta-analysis. Cochrane Database Syst Rev. 2020 Dec 2;12(12):CD006768. doi: 10.1002/14651858.CD006768.pub3.

Reference Type: DERIVED

PMID: 33263359 (View on PubMed)

Other Identifiers

1R21EY13164-1

Identifier Type: -

Identifier Source: secondary_id

1R21EY013164

Identifier Type: NIH

Identifier Source: secondary_id

View Link

HMS2040

Identifier Type: -

Identifier Source: org_study_id